Rusan Pharma, which specialises in pain management, opioid de-addiction & anti-infectives therapies, on Thursday said it aims to generate revenues of about Rs 600 crore over the next 2-3 years.
“We have clocked turnover of Rs 350 crore in FY17 and target to achieve Rs 600 crore in the next 2-3 years by expanding footprints in the overseas market,” Rusan Healthcare Business Head Malavika Saxena told PTI here.
Rusan has already received UK MHRA, South Africa -MCC, WHO-GMP approvals (of regulators) and is in the process of getting US FDA to target US and European market in an aggressive manner, she said.
The company presently generates 60 per cent revenues from exports. Rusan is one of the leading exporters of medicines to the CIS market, UK, and South Africa.
The company also has a strong presence across Europe, Asia Pacific, West Asia, Syria, Ethiopia, Sudan, Egypt, Bangladesh, UAE and Latin America, she said.
The firm is aiming to work with government-driven projects, Saxena added.
The company has three facilities at Kandla, Dehradun and Lisbon.
“We continue to grow and diversify by bringing quality pharmaceutical products, manufactured by advanced technology, and to accomplish our mission of satiating medical needs in even more regions of the world, she added.
To augment its research capability, the company invested Rs 100 crore in a R&D centre and a manufacturing unit at Kandla in Gujarat last year. With this fresh investment, it is now focused on research and manufacture of de-addiction and pain management drugs for domestic market and export.
The company’s R&D facility will help drive innovation in India and research for the next blockbuster drug, especially in the field of neglected diseases such as dengue, malaria, Alzheimer’s and Parkinson’s, she added.